Retatrutide dosing: what the studies used and how the units work

What is retatrutide, and what is a retatrutide dosing search asking?

Retatrutide, coded LY3437943 in early papers, is a single peptide with agonist activity at three receptors: GIP, GLP-1 and glucagon [2]. Because it has no approved label, there is no package insert, no pen and no labeled dosage. PinPoint's library lists it as investigational, logged by subcutaneous injection every 7 days, with a 144 hour half-life input [4].

A query such as retatrutide dose or reta dosage chart can hold three separate questions. Which amounts appeared in published studies? How does a vial measured in milligrams become a volume and a number of syringe units? And how is a weekly entry written down so that a history stays readable months later? Each answer comes from a different kind of source, and mixing them is how a study arm ends up mistaken for a personal schedule.

What retatrutide doses did the published studies report?

The first multiple-dose study, a phase 1b study in adults with type 2 diabetes published in 2022, gave once-weekly subcutaneous injections for 12 weeks in five ascending cohorts from 0.5 mg up to an escalated 12 mg, with the two highest cohorts reached through stepwise increases [1]. Its pharmacokinetics were dose proportional and the half-life was about six days, which is where the library's 144 hour input comes from [1][4].

The phase 2 obesity study randomised 338 adults to placebo or weekly retatrutide at 1 mg, 4 mg, 8 mg or 12 mg for 48 weeks [2]. The 4 mg and 8 mg arms each had versions with a 2 mg or a 4 mg initial amount, and the 12 mg arm began at 2 mg. At 48 weeks, mean body-weight change ranged from 8.7% lower in the 1 mg group to 24.2% lower in the 12 mg group, compared with 2.1% lower on placebo. Gastrointestinal events were the most common adverse events; they were dose related and were partly reduced by the lower initial amount [2].

A parallel phase 2 study in people with type 2 diabetes compared retatrutide with placebo and with an approved GLP-1 receptor agonist [3]. None of these papers converts its arms into instructions for an individual; they report what investigators assigned under monitoring. Separately, the app keeps 2, 4, 6, 9 and 12 mg as preset entry values so a weekly record can be typed quickly. Those presets are an input convenience, not a reading of the studies [4].

How do you convert retatrutide mg to mL and syringe units?

Research-catalog retatrutide arrives as powder, and the library's package example is a 10 mg vial from a supplier listing [4]. Concentration depends on only two numbers, the vial total and the final liquid volume, so one rule covers every case: amount divided by volume gives milligrams per millilitre, and millilitres times 100 gives U-100 syringe units [5].

The worked rows below use 2 mg because it is both the smallest app preset and an initial amount in several study arms; it appears in both sources, not because it suits anyone. Notice that 12 mg exceeds the whole 10 mg vial at any volume. The retatrutide dosing chart prints every preset against 1, 2 and 3 mL, and the retatrutide calculator accepts your own vial size and volume.

Water volume moves the syringe mark, never the milligrams. That is why how much bac water for 10 mg retatrutide has no arithmetic answer on its own: 1, 2 and 3 mL are all arithmetically valid divisions of the same 10 mg, and the volume itself belongs to preparation instructions that an unlabeled compound does not have. What keeps a later entry interpretable is recording the documented volume alongside the vial.

How do people log retatrutide in PinPoint?

A vial is set up once with its milligram total and water volume, and PinPoint returns the concentration and the syringe units to draw [6]. Each injection is then logged with compound, dose, site and pain level. For a weekly compound the schedule can be set to weekly, and titration phases let someone enter planned step-ups and step-downs so the calendar follows the plan they already have [6].

Reminders fire on the day and at the time chosen. The Home curve models levels between doses from the library's half-life input; at 144 hours one contribution halves over six days, so weekly entries overlap on the curve [6][4]. Modeled curves are mathematical visualizations of population averages and do not account for individual variation, and Ask PinPoint answers questions about published references without ever recommending a dose or a change [6].

What do people ask about retatrutide dosing?

What retatrutide dosing schedule did the studies use?

The three multiple-dose studies discussed here administered retatrutide once weekly by subcutaneous injection. In the phase 2 obesity study, arms reached 4, 8 or 12 mg from an initial 2 mg or 4 mg amount, and one arm stayed at 1 mg for 48 weeks. That is a research design, not a personal schedule.

How much bac water for 10 mg retatrutide?

No label specifies a volume, because retatrutide has no label. The arithmetic only shows what each volume would give: 1 mL gives 10 mg/mL, 2 mL gives 5 mg/mL and 3 mL gives about 3.33 mg/mL. The vial still holds 10 mg in every case.

What does a reta dosage chart show?

A chart lists amounts against volumes and U-100 units for one vial and one liquid volume, which is unit conversion. The PinPoint chart uses the library's 10 mg vial and its preset entry values and labels the rows as arithmetic.

Is retatrutide FDA approved?

No. Retatrutide is investigational and has no FDA label. Its human data come from phase 1 and phase 2 studies, and the library marks the entry as investigational.

Where do these facts come from?

Sources are listed by kind: labels first, then peer-reviewed papers, then PinPoint's own library, arithmetic and app description. Library values were retrieved from the PinPoint application on 5 October 2026; vendor listings support package sizes only.

1. Retatrutide phase 1b study in type 2 diabetes, 2022The Lancet, 2022. Multiple ascending doses of LY3437943 (retatrutide) given once weekly; pharmacokinetics and safety.Retrieved 2026-10-05 · study
2. Retatrutide phase 2 obesity study, 2023N Engl J Med, 2023. Once-weekly 1, 4, 8 and 12 mg arms with 2 mg or 4 mg initial doses, 48 weeks.Retrieved 2026-10-05 · study
3. Retatrutide phase 2 study in type 2 diabetes, 2023The Lancet, 2023. Randomised, placebo and active-controlled phase 2 study.Retrieved 2026-10-05 · study
4. PinPoint compound library, application recordsHalf-life inputs, routes, frequencies, package examples and confidence labels as stored in the iOS app library and mirrored in the peptide guides.Retrieved 2026-10-05 · library
5. Unit conversion arithmeticConcentration = amount / volume; volume = amount / concentration; U-100 units = mL x 100; remaining fraction = 2^(-elapsed / half-life).Retrieved 2026-10-05 · arithmetic
6. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description